• Nasodine Phase 3 common cold trial results published in prestigious journal
• Nasodine sales growth in Singapore and the US
• Placement raised $173,000, falling short of $1.6 million target
• Reviewing alternative funding for expansion and new product development

Firebrick Pharma Ltd (ASX:FRE) has provided its business activity update for the quarter ending 30 June 2025, along with its Appendix 4C quarterly cashflow report. The key highlights include the publication of the results of Firebrick's first Phase 3 clinical trial of Nasodine Nasal Spray (Nasodine) as a treatment for the common cold in the prestigious Frontiers in Medicine journal. The paper concluded that Nasodine demonstrated a consistently positive benefit in reducing overall cold severity and had a statistically significant and clinically meaningful impact on functional impairment (quality of life) scores. The company also reported on the progress with the marketing of Nasodine in Singapore and the US. In Singapore, sales receipts increased significantly in the June quarter, including a payment of $146k from DKSH, the company's retail distribution partner. Nasodine unit sales through Guardian pharmacies increased 36% in the June quarter versus the March quarter. Sales through the company's Singapore website also grew 8% in the June quarter. In the US, the operation is currently maintained as approximately cashflow neutral, with low base operating costs mostly covered by the profits from online sales. However, the company outlined a 'scale-up' plan for the US business in FY26 that involved several initiatives aimed at driving up US sales significantly over the next year. During the quarter, the company undertook a private placement through Report Card Pty Ltd (HotCopper), who acted as Lead Manager, raising $173,000, which fell far short of the target of $1.6 million. The company is now reviewing alternative funding for its planned expansion and new product development initiatives.

The company outlined a 'scale-up' plan for the US business in FY26 that involved several initiatives aimed at driving up US sales significantly over the next year, subject to new funding.